Cadrenal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 7.21 million. Basic loss per share from continuing operations was USD 0.57.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.413 USD | -3.98% | -10.37% | -44.28% |
1st Jan change | Capi. | |
---|---|---|
-44.28% | 6.89M | |
+32.39% | 694B | |
+29.39% | 593B | |
-1.38% | 371B | |
+20.00% | 331B | |
+7.23% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.45% | 169B |